MHRA (UK)
OTHER
MHRA Safety Roundup: August 2026
Published: 8/25/2026Detected: 9/4/2026
Summary preview
Summarises MHRA’s latest safety-related advice affecting how medicines and medical device users should interpret ongoing risk information.
Get the full analysis, free
Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.
Create free accountsafety
labeling
clinical
manufacturing
quality
#MHRA safety advice
#pharmacovigilance
#medical device vigilance
#risk communication
#labeling
Official Source Document Source Verified
Access the original document directly from MHRA.
More from MHRA (UK)
- Class 4 Medicines Defect Notification: Star Pharmaceuticals Ltd, Enalapril maleate/ Hydrochlorothiazide 20 mg/12.5 mg Tablets, EL(26)A/4811/12/2026
- Field Safety Notices from 02 to 06 November2026.11/10/2026
- Class 4 Medicines Defect Notification: Sandoz Limited, Co-Amoxiclav powder for oral suspension 250/62.5 mg/5mL, EL(26)A/4611/5/2026
- Class 3 Medicines Recall: Aspire Pharma Limited, Tropicamide 1% Eye Drops, solution in single dose containers 20 x 0.5ml , EL(26)A/4711/5/2026
- Field Safety Notices: 26 to 30 October 202611/4/2026